PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Neurobiol Aging. Author manuscript; available in PMC 2013 February 1.
Published in final edited form as:
PMCID: PMC2949683
NIHMSID: NIHMS210940

Polymorphisms in the GluR2 gene are not associated with amyotrophic lateral sclerosis

Abstract

Excitotoxicity is thought to play a pathogenic role in amyotrophic lateral sclerosis (ALS). Excitotoxic motor neuron death is mediated through the Ca2+-permeable AMPA-type of glutamate receptors and Ca2+ permeability is determined by the GluR2 subunit. We investigated whether polymorphisms or mutations in the GluR2 gene (GRIA2) predispose patients to ALS. Upon sequencing 24 patients and 24 controls no non-synonymous coding variants were observed but 24 polymorphisms were identified, 9 of which were novel. In a screening set of 310 Belgian ALS cases and 794 healthy controls and a replication set of 3,157 cases and 5,397 controls from 6 additional populations no association with susceptibility, age at onset or disease duration was observed. We conclude that polymorphisms in the GluR2 gene (GRIA2) are not a major contributory factor in the pathogenesis of ALS.

Keywords: Amyotrophic lateral sclerosis, excitotoxicity, GluR2, motor neuron

1. Introduction

Glutamate-induced cell death is thought to play a pathogenic role in amyotrophic lateral sclerosis. Excitotoxic motor neuron death is mediated by extensive Ca2+ entry into the cell through Ca2+-permeable AMPA receptors (Van Den Bosch et al., 2006). The Ca2+ permeability of AMPA receptors is determined by the presence or absence of the GluR2 subunit in the receptor complex. We have previously shown that lowering GluR2 aggravates mutant SOD1-induced motor neuron degeneration in mice (Van Damme et al., 2005), while Tateno et al. demonstrated that overexpression of GluR2 slowed down the motor neuron loss in this ALS model (Tateno et al., 2004). The question arises whether genetically determined differences in GluR2 expression could make humans more susceptible to diseases in which excitotoxicity is pathogenically involved. We therefore investigated whether polymorphisms in the GluR2 gene (GRIA2) are a risk factor for the development of ALS or a modifier of the disease phenotype.

2. Methods

The first sets of sporadic ALS patients were recruited from the university hospitals of Leuven and Antwerp. The control population consisted of healthy individuals from the same geographical area. The replication populations of in total 3,157 cases and 5,397 controls are described in references: Landers et al., 2009; Schymick et al., 2007; van Es et al., 2007; van Es et al., 2008 and van Es et al., 2009. Additional control data from the UK were obtained from 1,428 individuals from the British 1958 Birth Cohort DNA Collection (data deposited by the Wellcome Trust Sanger Institute and published online [http://www.b58cgene.sgul.ac.uk/]). SNP detection and genotyping was performed as described in the supplementary material.

3. Results

Because of the importance of AMPA receptor mediated excitotoxicity and more particularly the GluR2 subunit in ALS (Van Den Bosch et al., 2006), our aim was to clarify whether SNPs in the GluR2 gene could be a potential genetic risk factor for sporadic ALS. In order to investigate this hypothesis, we first identified the SNPs present in the GRIA2 gene. Sequencing all exons, including exon-intron boundaries and the 5′ and 3′ untranslated region of the GRIA2 gene in a subset of 24 ALS patients and 24 controls revealed 24 SNPs, of which 9 are unknown in the public SNP database (Ensembl release 54, July 2008) (Supplementary Table 1). Linkage disequilibrium analysis revealed 5 haplotype-tagging (ht) SNPs that capture 80% of the overall haplotype diversity. The 5 htSNPs were genotyped in 310 sporadic ALS cases and 794 controls. The frequency of rs6826285*T was lower in cases than controls (P=0.04, Supplementary Table 2). Adjusting for age and gender did not change these observations significantly. None of the SNPs was associated with age at onset (P>0.37). Genotype of none of the htSNPs was associated with survival in the Belgian study population while adjusting for age at onset and site of onset (P >0.25). Genotyping of SNP rs6826285 requires direct sequencing but the SNP is highly correlated (concordance 122/124 alleles, D′=0.92, r2=0.84) with rs10025251, which can be genotyped with high-throughput genotyping technologies. Hence we sought to corroborate the trend observed in the Belgian study population for rs6826285 by investigating rs10025251 in other available datasets from France, the Netherlands, Poland, Sweden, the UK and the US. The total study population consists of 3,467 cases and 6,191 controls. Overall genotyping success rate is >98%. Power is 99% to observe P<0.05 and 76% to observe P<10-3 for an odds ratio of 1.2 in the replication dataset, taking into account D′. No heterogeneity between populations was observed (Breslow-Day P=0.36). A meta-analysis using the Cochran-Mantel-Haenszel test stratified over country of origin resulted in P=0.40 for all populations and P=0.88 for the replication dataset (Figure 1).

Figure 1
Meta-analysis in a study population of 3,467 cases and 6,191 controls. The abbreviations stand for Belgium (BEL), France (FRA), the Netherlands (NL), Poland (PL), Sweden (SWE), the United Kingdom (UK) and the United States (US).

4. Discussion

We found no evidence for an association of GluR2 SNPs with ALS. However, this does not exclude a differential GluR2 regulation between ALS patients and control individuals as there are multiple other mechanisms described that regulate GluR2-subunit-containing AMPARs (Isaac et al., 2007). GluR2 mRNA is regulated by editing, splicing and mRNA transport to dendrites and its local translation (Isaac et al., 2007; Ju et al., 2004). In the context of ALS, this becomes particularly interesting as mutations in TDP-43 and FUS/TLS, which are RNA binding molecules, were recently discovered as genetic causes of the disease (Lagier-Tourenne and Cleveland, 2009). Moreover, assembly of the receptor complex and incorporation of the GluR2 lacking AMPA receptors into the synapse are also tightly regulated processes that could be disturbed in ALS or could predispose patients to develop the disease (Isaac et al., 2007). In addition (growth) factors secreted by surrounding cells, which are also thought to play a dominant role in the pathogeneses, could also influence the expression level of the GluR2 subunit. We recently showed that differences in astrocytic factors modulate the GluR2 expression in motor neurons and so the susceptibility of motor neurons to excitotoxicity (Van Damme et al., 2007). Furthermore the vascular endothelial growth factor, which is also secreted by astrocytes, is capable of inducing GluR2 expression levels (Bogaert et al., 2009). In conclusion, we observed a lack of association in the GluR2 subunit in SALS which doesn't exclude the possibility that GluR2 is differentially regulated in ALS patients and controls.

Supplementary Material

Acknowledgments

This work was supported in part by grants from the University of Leuven, the American ALS Association, the Interuniversity Attraction Poles, program P6/43 of the Belgian Science Policy Office (BELSPO), by a grant of the Jagiellonian University (Krakow, Poland; n° K/ZDS/001076), by the Intramural Research Program of the NIH, National Institute on Aging (Z01-AG000949-02) and by the Packard Center for ALS Research. E.B. is a research assistant, K.S. is a postdoctoral fellow and P.V.D. is a clinical investigator of the Fund for Scientific Research – Flanders (FWO-V). W.R. is supported through the E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders and C.V.B. by a Methusalem excellence grant of the Flanders government. R.H.B. Jr receives supports from the ALS Therapy Alliance, Project ALS, the Angel Fund, the Pierre L. de Bourgknecht ALS Research Foundation, the Al-Athel ALS Research Foundation, the ALS Family Charitable Foundation, and the National Institute for Neurological Disorders and Stroke. We acknowledge use of genotype data from the British 1958 Birth Cohort DNA collection, funded by the Medical Research Council grant G0000934 and the Wellcome Trust grant 068545/Z/02.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

  • Abecasis GR, Cookson WO. GOLD--graphical overview of linkage disequilibrium. Bioinformatics. 2000;16:182–3. [PubMed]
  • Bogaert E, Van Damme P, Poesen K, Dhondt J, Hersmus N, Kiraly D, Scheveneels W, Robberecht W, Van Den Bosch L. VEGF protects motor neurons against excitotoxicity by upregulation of GluR2. Neurobiol Aging 2009 [PubMed]
  • Isaac JT, Ashby M, McBain CJ. The role of the GluR2 subunit in AMPA receptor function and synaptic plasticity. Neuron. 2007;54:859–71. [PubMed]
  • Ju W, Morishita W, Tsui J, Gaietta G, Deerinck TJ, Adams SR, Garner CC, Tsien RY, Ellisman MH, Malenka RC. Activity-dependent regulation of dendritic synthesis and trafficking of AMPA receptors. Nat Neurosci. 2004;7:244–53. [PubMed]
  • Kawahara Y, Ito K, Sun H, Aizawa H, Kanazawa I, Kwak S. Glutamate receptors: RNA editing and death of motor neurons. Nature. 2004;427:801. [PubMed]
  • Lagier-Tourenne C, Cleveland DW. Rethinking ALS: the FUS about TDP-43. Cell. 2009;136:1001–4. [PMC free article] [PubMed]
  • Landers JE, Melki J, Meininger V, Glass JD, van den Berg LH, van Es MA, Sapp PC, van Vught PW, McKenna-Yasek DM, Blauw HM, Cho TJ, Polak M, Shi L, Wills AM, Broom WJ, Ticozzi N, Silani V, Ozoguz A, Rodriguez-Leyva I, Veldink JH, Ivinson AJ, Saris CG, Hosler BA, Barnes-Nessa A, Couture N, Wokke JH, Kwiatkowski TJ, Jr, Ophoff RA, Cronin S, Hardiman O, Diekstra FP, Leigh PN, Shaw CE, Simpson CL, Hansen VK, Powell JF, Corcia P, Salachas F, Heath S, Galan P, Georges F, Horvitz HR, Lathrop M, Purcell S, Al-Chalabi A, Brown RH., Jr Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2009;106:9004–9. [PubMed]
  • Myers SJ, Huang Y, Genetta T, Dingledine R. Inhibition of glutamate receptor 2 translation by a polymorphic repeat sequence in the 5′-untranslated leaders. J Neurosci. 2004;24:3489–99. [PubMed]
  • Schymick JC, Scholz SW, Fung HC, Britton A, Arepalli S, Gibbs JR, Lombardo F, Matarin M, Kasperaviciute D, Hernandez DG, Crews C, Bruijn L, Rothstein J, Mora G, Restagno G, Chio A, Singleton A, Hardy J, Traynor BJ. Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. 2007;6:322–8. [PubMed]
  • Tateno M, Sadakata H, Tanaka M, Itohara S, Shin RM, Miura M, Masuda M, Aosaki T, Urushitani M, Misawa H, Takahashi R. Calcium-permeable AMPA receptors promote misfolding of mutant SOD1 protein and development of amyotrophic lateral sclerosis in a transgenic mouse model. Hum Mol Genet. 2004;13:2183–96. [PubMed]
  • Van Damme P, Bogaert E, Dewil M, Hersmus N, Kiraly D, Scheveneels W, Bockx I, Braeken D, Verpoorten N, Verhoeven K, Timmerman V, Herijgers P, Callewaert G, Carmeliet P, Van Den Bosch L, Robberecht W. Astrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity. Proc Natl Acad Sci U S A. 2007;104:14825–30. [PubMed]
  • Van Damme P, Braeken D, Callewaert G, Robberecht W, Van Den Bosch L. GluR2 deficiency accelerates motor neuron degeneration in a mouse model of amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2005;64:605–12. [PubMed]
  • Van Den Bosch L, Van Damme P, Bogaert E, Robberecht W. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta. 2006;1762:1068–82. [PubMed]
  • van Es MA, Van Vught PW, Blauw HM, Franke L, Saris CG, Andersen PM, Van Den Bosch L, de Jong SW, van't Slot R, Birve A, Lemmens R, de Jong V, Baas F, Schelhaas HJ, Sleegers K, Van Broeckhoven C, Wokke JH, Wjmenga C, Robberecht W, Veldink JH, Ophoff RA, van den Berg LH. ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. Lancet Neurol. 2007;6:869–77. [PubMed]
  • van Es MA, van Vught PW, Blauw HM, Franke L, Saris CG, Van den Bosch L, de Jong SW, de Jong V, Baas F, van't Slot R, Lemmens R, Schelhaas HJ, Birve A, Sleegers K, Van Broeckhoven C, Schymick JC, Traynor BJ, Wokke JH, Wjmenga C, Robberecht W, Andersen PM, Veldink JH, Ophoff RA, van den Berg LH. Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral sclerosis. Nat Genet. 2008;40:29–31. [PubMed]
  • van Es MA, Veldink JH, Saris CG, Blauw HM, van Vught PW, Birve A, Lemmens R, Schelhaas HJ, Groen EJ, Huisman MH, van der Kooi AJ, de Visser M, Dahlberg C, Estrada K, Rivadeneira F, Hofman A, Zwarts MJ, van Doormaal PT, Rujescu D, Strengman E, Giegling I, Muglia P, Tomik B, Slowik A, Uitterlinden AG, Hendrich C, Waibel S, Meyer T, Ludolph AC, Glass JD, Purcell S, Cichon S, Nothen MM, Wichmann HE, Schreiber S, Vermeulen SH, Kiemeney LA, Wokke JH, Cronin S, McLaughlin RL, Hardiman O, Fumoto K, Pasterkamp RJ, Meininger V, Melki J, Leigh PN, Shaw CE, Landers JE, Al-Chalabi A, Brown RH, Jr, Robberecht W, Andersen PM, Ophoff RA, van den Berg LH. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet. 2009;41:1083–7. [PubMed]